To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
405 Current news of Merckrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
€ 25 million investment in Molsheim
Merck will add a single-use assembly production unit at its Life Science Center in Molsheim, France. With the € 25 million investment, the company is accelerating its European expansion plans for this key technology, which is used for the production of Covid-19 vaccines and other lifesaving ...
Merck had a successful fiscal 2020, a year that was marked by the Covid-19 pandemic. The company increased its sales, expanded its EBITDA pre margin and met all the financial targets it had set for itself. The key drivers were the business with products and services for pharmaceutical ...
Accelerated Supply of Urgently Needed Lipids
Merck and BioNTech are further expanding their strategic partnership. Merck, in close collaboration with BioNTech, will significantly accelerate the supply of urgently needed lipids and increase the amount of lipid delivery towards the end of 2021. The lipids will be used for the production of ...
Rehan Verjee leaves his position as President of EMD Serono and Global Head of Innovative Medicine Franchises
Merck, a leading science and technology company, today announced that Rehan Verjee has made the decision to leave his position as President of EMD Serono and Global Head of Innovative Medicine Franchises, to pursue an opportunity outside of Merck that will soon be announced. He will be succeeded ...
Merck announced the acquisition of AmpTec, a leading Hamburg, Germany-based, mRNA contract development and manufacturing organization (CDMO). The deal strengthens Merck’s capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments and diagnostics applicable in ...
Global coronavirus pandemic has significantly increased demand
Merck announced the broadening of its manufacturing footprint with a combined € 40 million investment at its production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire, USA. These sites supply critical products to customers developing lifesaving therapies, including Covid-19 ...
Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology
Merck and Artios Pharma Limited, a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, announced a global three year strategic research collaboration to discover and develop multiple precision oncology drugs. “Our platform has ...
Merck invests € 10 million in modular technical infrastructure
Merck announced a collaborative partnership with Siemens for the digitalization of production. This partnership is to result in the development of a process control system for the modular production of innovative materials and products for the electronics, pharmaceutical and life science ...
In comparison with the year-earlier quarter, Group net sales increased by 9.7% to € 4.4 billion
Merck grew significantly in the third quarter. In comparison with the year-earlier quarter, Group net sales increased by 9.7% to € 4.4 billion. The increase was primarily due to double-digit percentage organic growth in the Life Science business sector and acquisition-related increases in the ...
Once approved, new test will help laboratories increase testing capacity and decrease turnaround time for results
Merck announced a collaboration with Mammoth Biosciences Inc., of South San Francisco, California, USA, for the development, scale-up and commercial production of Mammoth’s CRISPR-based SARS CoV-2 diagnostic test. Mammoth’s high-throughput systems will be compatible with both nasal swab and ...